Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication February 23, 2018
- Accepted for publication March 22, 2018
- Published online September 4, 2018.
Article Versions
- previous version (April 6, 2018 - 09:18).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Thomas Lindner*,1,
- Anastasia Loktev*,1–3,
- Annette Altmann1,2,
- Frederik Giesel1,
- Clemens Kratochwil1,
- Jürgen Debus4,5,
- Dirk Jäger6,
- Walter Mier1 and
- Uwe Haberkorn1,2
- 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
- 2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany
- 3Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
- 4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- 5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; and
- 6Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany
- For correspondence or reprints contact: Uwe Haberkorn, Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail: uwe.haberkorn{at}med.uni-heidelberg.de
↵* Contributed equally to this work.
Cited By...
Article usage
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
Jump to section
Related Articles
Cited By...
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- {alpha}v{beta}6-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection
- Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
- A Conversation Between Uwe Haberkorn and Johannes Czernin
- Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention
- The Future of Nuclear Medicine as an Independent Specialty
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Novel Structured Reporting Systems for Theranostic Radiotracers
- 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers